FDA delays key advisory committee meeting on OTC birth control

In the NewsArticle

Oct 26

Roll Call covers the postponement of the FDA advisory committee meeting to review HRA Pharma’s application for making its daily progestin-only birth control pill, Opill, available over the counter.

costFDAinsurance coverageOTC accesspolicymakersUnited StatesUS Supreme Court

Free the Pill

FDA delays key advisory committee meeting on OTC birth control

FDA postpones meeting to review over-the-counter birth control pills

Young people overwhelmingly struggle to access birth control: Study